SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 136 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $236,387,971 | +49.1% | 1,950,074 | +40.8% | 0.05% | +54.5% |
| Q2 2023 | $158,554,429 | +16.0% | 1,384,513 | +39.6% | 0.03% | +6.5% |
| Q1 2023 | $136,743,073 | +21.7% | 992,114 | +14.5% | 0.03% | +19.2% |
| Q4 2022 | $112,317,482 | +96.0% | 866,781 | +67.2% | 0.03% | +100.0% |
| Q3 2022 | $57,318,000 | -1.4% | 518,522 | -33.1% | 0.01% | -13.3% |
| Q2 2022 | $58,133,000 | -10.0% | 775,523 | -6.2% | 0.02% | +15.4% |
| Q1 2022 | $64,605,000 | +2.5% | 826,988 | +18.2% | 0.01% | 0.0% |
| Q4 2021 | $63,010,000 | -39.4% | 699,727 | -37.8% | 0.01% | -40.9% |
| Q3 2021 | $104,060,000 | +26.8% | 1,125,204 | +6.6% | 0.02% | +22.2% |
| Q2 2021 | $82,059,000 | +30.3% | 1,055,559 | +24.9% | 0.02% | +20.0% |
| Q1 2021 | $62,983,000 | -40.5% | 845,071 | +36.1% | 0.02% | -46.4% |
| Q4 2020 | $105,854,000 | +37.6% | 620,882 | +13.3% | 0.03% | +21.7% |
| Q3 2020 | $76,943,000 | +3.7% | 547,911 | +18.4% | 0.02% | -11.5% |
| Q2 2020 | $74,222,000 | +6.9% | 462,902 | -34.8% | 0.03% | -16.1% |
| Q1 2020 | $69,433,000 | -54.6% | 709,802 | -40.2% | 0.03% | -53.7% |
| Q4 2019 | $153,083,000 | +98.1% | 1,186,317 | +15.6% | 0.07% | +81.1% |
| Q3 2019 | $77,295,000 | -26.3% | 1,026,230 | +48.7% | 0.04% | -22.9% |
| Q2 2019 | $104,856,000 | +36.1% | 690,068 | +6.8% | 0.05% | +26.3% |
| Q1 2019 | $77,046,000 | +31.7% | 646,410 | +20.6% | 0.04% | +18.8% |
| Q4 2018 | $58,486,000 | -53.8% | 535,927 | -31.6% | 0.03% | -43.9% |
| Q3 2018 | $126,610,000 | +7.9% | 783,911 | -11.7% | 0.06% | -1.7% |
| Q2 2018 | $117,338,000 | +443.3% | 887,714 | +204.5% | 0.06% | +383.3% |
| Q1 2018 | $21,597,000 | -47.5% | 291,487 | -60.6% | 0.01% | -52.0% |
| Q4 2017 | $41,173,000 | -61.9% | 740,002 | -68.9% | 0.02% | -69.9% |
| Q3 2017 | $107,992,000 | +175.3% | 2,380,790 | +104.6% | 0.08% | +151.5% |
| Q2 2017 | $39,234,000 | +65.6% | 1,163,869 | +45.4% | 0.03% | +57.1% |
| Q1 2017 | $23,687,000 | +9.3% | 800,228 | +1.2% | 0.02% | -8.7% |
| Q4 2016 | $21,680,000 | -72.7% | 790,360 | -39.0% | 0.02% | -71.6% |
| Q3 2016 | $79,534,000 | +2432.1% | 1,295,139 | +686.2% | 0.08% | +1925.0% |
| Q2 2016 | $3,141,000 | -89.4% | 164,743 | -89.2% | 0.00% | -89.2% |
| Q1 2016 | $29,710,000 | -5.4% | 1,522,052 | +87.0% | 0.04% | +8.8% |
| Q4 2015 | $31,410,000 | +6.6% | 814,146 | -11.3% | 0.03% | +21.4% |
| Q3 2015 | $29,478,000 | +758.4% | 918,047 | +713.6% | 0.03% | +833.3% |
| Q2 2015 | $3,434,000 | +1373.8% | 112,842 | +543.7% | 0.00% | – |
| Q1 2015 | $233,000 | -52.6% | 17,531 | -48.4% | 0.00% | – |
| Q4 2014 | $492,000 | -18.3% | 33,978 | +19.0% | 0.00% | -100.0% |
| Q3 2014 | $602,000 | +359.5% | 28,546 | +547.6% | 0.00% | – |
| Q2 2014 | $131,000 | +61.7% | 4,408 | +158.5% | 0.00% | – |
| Q3 2013 | $81,000 | -97.9% | 1,705 | -98.3% | 0.00% | -100.0% |
| Q2 2013 | $3,835,000 | – | 100,794 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |